[Neonatal immunology and cord blood transplantation].
The increased susceptibility of human newborns to infections is usually ascribed to the immaturity of the neonatal immune system. The neonatal immune system has never met microbial antigens, and thus the repertoire of its adaptative arm (T and B cells) is entirely pre-immune, or "naïve". However this neonatal pre-immune repertoire is similar to the adult pre-immune repertoire, and cord blood natural killer cells studies show that the innate immunity cells harbor the full killing machinery that characterize mature cells. Moreover, human neonates are able to show an adult-like allogeneic response. Taken together, several lines of evidence suggest that the neonatal immune system, although naïve, is fully mature. However, newborns display phenotypic and functional differences with adults in both adaptative and innate arms. Specific properties may explain these differences, as high number of regulatory T cells, low plasmacytoid dendritic cell response to stimuli and high IL-10 production. These properties are in line with the high susceptibility of newborns to infections and the low incidence of graft-versus-host-disease after cord blood transplantation. To explain these differences, we introduce a new model. Although naive, the neonatal immune system is mature, and these functional differences are due to a message originating from the placenta and aimed at inducing the foetus tolerance to its mother. Full understanding of the involved mechanisms will help to protect the newborn against infections and to improve cord blood transplantation outcome.
Charrier
Emily
E
Laboratoire d'Immunovirologie et de Recherche sur le Sang de Cordon, Centre de Cancérologie Charles-Bruneau, Centre de Recherche, Hôpital Sainte-Justine, Université de Montréal, Montréal (Québec), Canada.
Dardari
R'Kia
R
Michaud
Annie
A
Cordeiro
Paulo
P
Duval
Michel
M
D036101:Cord Blood Stem Cell Transplantation; D006801:Humans; D007108:Immune Tolerance; D007231:Infant, Newborn; D007239:Infections / Q000276:immunology* / Q000628:therapy*